Logotype for RaySearch Laboratories

RaySearch Laboratories (RAY) Q4 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for RaySearch Laboratories

Q4 2024 earnings summary

23 Dec, 2025

Executive summary

  • Net sales reached SEK 323 million in Q4 2024, up 8% year-over-year, and SEK 1.192 billion for the full year, up 17% year-over-year, marking a record high.

  • Operating profit was SEK 74 million in Q4 (23% margin) and SEK 260 million for the year (22% margin), both significantly improved from prior year and exceeding the 2026 margin target.

  • Support revenue grew 14% in 2024, now 40% of total sales, driven by new license sales and high customer retention.

  • Board proposed increasing the dividend to SEK 3 per share, reflecting strong financial position and outlook.

  • Strong cash position of SEK 463 million at year-end, with stable cash flow and no loans.

Financial highlights

  • Q4 order intake was SEK 305 million, down 4% year-over-year; full-year order intake grew 8% to SEK 1.087 billion.

  • License sales in Q4 were SEK 160 million, up 16% year-over-year; support revenue was SEK 131 million, up 9%.

  • Full-year license revenue was SEK 575.5 million (+30%), support revenue SEK 472.9 million (+14%), and hardware revenue SEK 109.2 million (down from SEK 128.4 million).

  • Q4 profit after tax was SEK 60 million; full-year profit after tax was SEK 203.5 million.

  • Cash flow from operations in Q4 was SEK 103 million; full-year cash flow from operations improved to SEK 485 million.

Outlook and guidance

  • Positive outlook for order intake and revenue growth in 2025, with continued momentum expected.

  • Operating margin target raised to at least 25% by 2026, up from previous 20%, after exceeding the target in 2024.

  • No drastic changes in OPEX planned for 2025; growth in headcount and investments to continue at a similar pace as previous years.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more